DYN · Dyne Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on DYN. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About DYN · Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Live Quote
BUY (score +7) · 12-1 mom 63.4% · RSI 60.4 · above_both · -16.6% from high
Targets blend Wall Street consensus (16 analysts: low $17.00 / mean $38.25 / high $50.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage crashed before producing an artifact (e.g. LM Studio timeout, malformed JSON, network error). The cooldown will hold this off the queue for ~1h before retry.
Score of 25 falls well below the 45 threshold. The dossier flags material anti-signals (anticipated dilution from the doubled share authorization and low liquidity) that, combined with a ~$140M/quarter burn rate, create substantial overhang risk. The binary catalyst is already reflected in elevated IV, and the lack of traditional valuation metrics or broad insider buying makes this a speculative setup rather than a publishable thesis.
Dyne is a clinical-stage neuromuscular biotech whose BLA submission on May 26 triggered the investigation's smart-money trigger. Director Brian Posner made two verified open-market P-code purchases totaling ~$70K at $18.21 and $16.94 in late May/early June — genuinely clustered within 14 days. Three other directors received stock-option grants (vesting 2027) on June 5, which are compensation instruments, not directional signals. The company has two near-term catalysts: z-rostudirsen BLA filed for DMD accelerated approval (decision expected Q1 2027), and ACHIEVE REC topline data due Q1 2027 for DM1. Valuation is binary-biased by definition — no FCF, pre-revenue — but the analyst consensus target of $38 implies ~114% upside from current levels. The main risk: share count was just doubled (200M→400M authorized) suggesting anticipated ATM dilution ahead of launch costs.